Palisade Bio (NASDAQ:PALI) Posts Earnings Results, Beats Estimates By $1.70 EPS

Palisade Bio (NASDAQ:PALI) posted its quarterly earnings results on Monday. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.39) by $1.70, Zacks reports.

Palisade Bio Stock Down 1.4 %

PALI stock opened at $0.70 on Tuesday. The company has a 50 day moving average of $1.12 and a two-hundred day moving average of $2.17. The company has a market cap of $1.94 million, a price-to-earnings ratio of -0.05 and a beta of 1.49. Palisade Bio has a 12-month low of $0.66 and a 12-month high of $9.65.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.